Osteopontin Expression in Cardiomyocytes Is Increased in Pediatric Patients With Sepsis or Pneumonia

Camila Iansen Irion1,2, Kiera Parrish2, Krista John-Williams1,2

  • 1Interdisciplinary Stem Cell Institute, University of Miami Leonard M. Miller School of Medicine, Miami, FL, United States.

Frontiers in Physiology
|January 9, 2019
PubMed

Insights

Osteopontin (OPN) expression increased in pediatric hearts with sepsis or pneumonia. This finding suggests OPN may play a role in sepsis- and pneumonia-induced cardiac dysfunction in children.

Area of Science:

  • Cardiovascular Science
  • Immunology
  • Pediatric Pathology

Background:

  • Sepsis and pneumonia are leading causes of death in the U.S.
  • Both conditions involve inflammation, immune dysfunction, and cardiovascular dysfunction.
  • The role of Osteopontin (OPN) in sepsis/pneumonia-induced cardiac dysfunction, particularly in pediatric patients, is not well understood.

Purpose of the Study:

  • To investigate Osteopontin (OPN) expression in cardiomyocytes of pediatric and adult patients with sepsis and/or pneumonia.
  • To determine if OPN expression correlates with cardiac dysfunction in these patient groups.

Main Methods:

  • Human myocardial autopsy tissues from pediatric and adult patients (with and without sepsis/pneumonia) were analyzed.
  • Immunofluorescence staining was used to detect OPN expression in cardiomyocytes, co-stained with myocyte markers (ACTA1, MLC2).
  • Quantitative analysis measured OPN-positive cardiomyocytes.

Main Results:

  • OPN expression was significantly elevated in cardiomyocytes of pediatric patients with sepsis/pneumonia compared to non-septic pediatric controls and adult/elderly septic patients.
  • In older septic patients, elevated OPN expression was associated with severe coronary arterial occlusion.
  • This is the first study to report increased OPN expression in pediatric cardiomyocytes during sepsis or pneumonia.

Conclusions:

  • Increased Osteopontin (OPN) expression in cardiomyocytes is a feature of sepsis and pneumonia in pediatric patients.
  • OPN may be a significant factor in sepsis- or pneumonia-related cardiac dysfunction in children.
  • Further research is warranted to explore OPN's specific mechanisms in pediatric cardiac complications.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
259
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
304
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
223
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
292
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
882
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
2.9K